The conclusion is that the trispecific SAR442257 operates via dual targeting of CD38 and CD28 on myeloma cells and of CD3 and CD28 on T lymphocytes, showing superior MM killing compared to bispecific antibodies. This evidence concerns the gene CD38 and Miyoshi myopathy.